We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Advanced Melanoma

Journal Scan / Research · February 01, 2021

Tebentafusp Induces Anti-Tumor Immune Responses in Patients With Metastatic Melanoma

Clinical Cancer Research


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
Tebentafusp, a TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients With Metastatic Melanoma
Clin. Cancer Res 2020 Nov 15;26(22)5869-5878, MR Middleton, C McAlpine, VK Woodcock, P Corrie, JR Infante, NM Steven, TRJ Evans, A Anthoney, AN Shoushtari, O Hamid, A Gupta, A Vardeu, E Leach, R Naidoo, S Stanhope, S Lewis, J Hurst, I O'Kelly, M Sznol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading